Quarterly ResultAug 5, 2026, 04:03 PM
Carlsmed Q2 Revenue $18.9M, +57%; Raises FY26 Guidance to $74-78M
AI Summary
Carlsmed reported strong second quarter 2026 financial results, with revenue reaching $18.9 million, marking a 57% year-over-year increase. The company raised its full-year 2026 revenue guidance to a range of $74 million to $78 million, driven by growing momentum in aprevo® procedures and significant surgeon adoption. Despite the revenue growth and expanded gross margins, the net loss for the quarter increased to ($10.5) million, and adjusted EBITDA was ($8.6) million.
Key Highlights
- Q2 2026 revenue was $18.9 million, a 57% increase year-over-year.
- Full-year 2026 revenue guidance raised to $74 million to $78 million.
- Gross margin expanded to 76.8% in Q2 2026, up from 73.4% in Q2 2025.
- Net loss for Q2 2026 was ($10.5) million, compared to ($6.8) million in Q2 2025.
- Adjusted EBITDA for Q2 2026 was ($8.6) million, compared to ($6.2) million in Q2 2025.
- Total trained surgeon users increased over 60% year-over-year.
- aprevo® cervical procedures now represent approximately 10% of quarterly revenue.
- Cash and cash equivalents totaled $89.3 million as of June 30, 2026.
Price Impact
More from CARL